Related references
Note: Only part of the references are listed.ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2
D. L. F. Chang et al.
ONCOGENE (2007)
A negative feedback signaling network underlies oncogene-induced senescence
Stephanie Courtois-Cox et al.
CANCER CELL (2006)
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression
M. A. Christophorou et al.
NATURE (2006)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T. Eisen et al.
BRITISH JOURNAL OF CANCER (2006)
Cellular senescence in naevi and immortalisation in melanoma: a role for p16?
V. C. Gray-Schopfer et al.
BRITISH JOURNAL OF CANCER (2006)
Amplification of CDK4 and MDM2 in malignant melanoma
V Muthusamy et al.
GENES CHROMOSOMES & CANCER (2006)
Genetic alterations in signaling pathways in melanoma
FG Haluska et al.
CLINICAL CANCER RESEARCH (2006)
Comprehensive analysis of CDKN2A (p16(INK4A)/p14(ARF)) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma
K Laud et al.
JOURNAL OF MEDICAL GENETICS (2006)
Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi
Pablo Uribe et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma
Vikas K. Goel et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
BRAFE600-associated senescence-like cell cycle arrest of human naevi
C Michaloglou et al.
NATURE (2005)
Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background
J Ackermann et al.
CANCER RESEARCH (2005)
Mutant V599EB-RAF regulates growth and vascular development of malignant melanoma tumors
A Sharma et al.
CANCER RESEARCH (2005)
Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases
DL Dai et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma
EE Patton et al.
CURRENT BIOLOGY (2005)
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
H Tsao et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Deregulated Akt3 activity promotes development of malignant melanoma
JM Stahl et al.
CANCER RESEARCH (2004)
Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo
NE Sharpless et al.
ONCOGENE (2003)
PTEN signaling pathways in melanoma
H Wu et al.
ONCOGENE (2003)
High frequency of BRAF mutations in nevi
PM Pollock et al.
NATURE GENETICS (2003)
Tyrosinase-Cre mice for tissue-specific gene ablation in neural crest and neuroepithelial-derived tissues
ID Tonks et al.
GENESIS (2003)
A genome-based strategy uncovers frequent BRAF mutations in melanoma
PM Pollock et al.
CANCER CELL (2002)
Dual inactivation of RB and p53 pathways in RAS-induced melanomas
N Bardeesy et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Share Paper
